ArticleThe Laryngoscope2026
Neoadjuvant Therapies for Thyroid Cancer: A Scoping Review.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSurgery is the definitive treatment for most thyroid cancers. However, anaplastic thyroid carcinoma (ATC) and other undifferentiated thyroid cancers are often unresectable and carry high mortality. Case reports and series have described neoadjuvant therapies, including chemotherapy, targeted therapy, radiation, and radioactive iodine, to improve resectability. This review evaluates the efficacy and safety of neoadjuvant therapy in unresectable thyroid cancers. DATA SOURCES: PubMed, Embase, and Web of Science. REVIEW
methodsA comprehensive literature search was performed through August 2025 following PRISMA-ScR guidelines. English-language studies reporting patient-specific data on thyroid cancer diagnosis and neoadjuvant treatment were included. Using Covidence, patient demographics, neoadjuvant therapies, surgical interventions, and outcomes were extracted from 87 studies following inclusion and exclusion criteria.
resultsIndividual patient data were available for 122 patients from 61 studies. The most common cancers were papillary thyroid carcinoma (PTC), ATC, and differentiated thyroid carcinoma (DTC). The median age was 61 years, 54% female. TNM staging was 68% T4, 69% N1, and 51% M0. Frequent mutations included BRAFV600E (N = 31), RET (N = 18), TERT (N = 12), and TP53 (N = 12). Lenvatinib (N = 46) and dabrafenib and trametinib (N = 26) were the most used. Total thyroidectomy occurred in 53% of patients. Post-neoadjuvant therapy outcomes included partial response (64%) and complete response (10%), with subsequent R0 (N = 62), R1 (N = 38), and R2 (N = 10) surgical resections.
conclusionNeoadjuvant therapy shows promise in improving resectability for unresectable and poorly differentiated thyroid cancers, with 51% of patients achieving R0 resection. Future studies should investigate optimal therapy selection, timing, dosing, and long-term outcomes, including disease-specific survival and patient-reported measures. LEVEL OF EVIDENCE: NA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.